Search

Displaying results 1791 - 1800 of 3015 in total
  1. Drug

    V1003

    go.drugbank.com/drugs/DB05046
    Experimental

    V1003 is an intranasal formulation of buprenorphine, an opiate analgesic, for the management of post-operative pain in hospital and home settings. Buprenorphine is a well-known analgesic and the intranasal formulation has the potential t...

  2. Drug

    Mecasermin rinfabate

    go.drugbank.com/drugs/DB14751
    ApprovedInvestigational

    Mecasermin rinfabate manufactured by Insmed Incorporated under the brand name Iplex was approved by the FDA in 2005[L5722].

  3. Drug

    Meprobamate

    go.drugbank.com/drugs/DB00371
    ApprovedIllicit

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p603) Meprobamate is a controlled substance in the U.S.

  4. Drug

    Palifermin

    go.drugbank.com/drugs/DB00039
    ApprovedInvestigational

    It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.[L17933]

  5. Drug

    Ponatinib

    go.drugbank.com/drugs/DB08901
    ApprovedInvestigational

    FDA approved on December 14, 2012.

  6. Drug

    Rilonacept

    go.drugbank.com/drugs/DB06372
    ApprovedInvestigational

    Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS...

  7. Drug

    Vapitadine

    go.drugbank.com/drugs/DB05738
    Experimental

    An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses.

  8. Drug

    Oseltamivir

    go.drugbank.com/drugs/DB00198
    ApprovedInvestigational

    They recommend the use of oseltamivir in people with a higher risk of developing complications including children younger than 2 years, people over 65 years, people with some chronic conditions or immunosuppression

  9. Drug

    Alaproclate

    go.drugbank.com/drugs/DB13233
    Experimental

    Development was discontinued due to concerns over hepatotoxicity observed in animal studies.

  10. Drug

    Pegaptanib

    go.drugbank.com/drugs/DB04895
    ApprovedWithdrawn

    Pegaptanib was granted FDA approval on 17 September 2004.[L17903]